Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: AGGRENOX

« Back to Dashboard
Aggrenox is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from four suppliers. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-four countries.

The generic ingredient in AGGRENOX is aspirin; dipyridamole. There are eighteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.

Summary for Tradename: AGGRENOX

Patents:1
Applicants:1
NDAs:1
Suppliers: see list4
Formulation / Manufacturing:see details

Clinical Trials for: AGGRENOX

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers
Status: Completed Condition: Healthy

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers
Status: Completed Condition: Healthy

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
Status: Completed Condition: Stroke

Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers
Status: Completed Condition: Healthy

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
Status: Completed Condition: Cerebrovascular Accident

Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH
Status: Completed Condition: Healthy

EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
Status: Completed Condition: Cerebrovascular Accident

Headache Study to Compare Aggrenox Full Dose and Reduced Dose
Status: Completed Condition: Cerebrovascular Accident

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects
Status: Completed Condition: Healthy

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects
Status: Terminated Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
AGGRENOX
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL020884-001Nov 22, 1999RXYes6,015,577<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: AGGRENOX

Drugname Dosage Strength RLD Submissiondate
aspirin and dipyridamoleExtended-release Capsules25 mg and 200 mgAggrenox2/1/2007

International Patent Family for Tradename: AGGRENOX

Country Document Number Publication Date
Singapore122593Jun 10, 1994
Philippines27176Apr 02, 1993
Israel83510Jan 31, 1988
Netherlands990001Mar 01, 1999
Ireland872152Feb 13, 1988
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc